Lanadelumab
Lanadelumab: A Promising Therapy for Hereditary Angioedema
Lanadelumab (INN), marketed under the trade name Takhzyro, is a human monoclonal antibody (class IgG1 kappa) that has garnered significant attention for its potential in the treatment of hereditary angioedema. By targeting plasma kallikrein (pKal), Lanadelumab works towards the prevention of angioedema attacks in affected patients.
Mechanism of Action
Lanadelumab exerts its therapeutic action by targeting the plasma kallikrein (pKal). By inhibiting this protein, the drug reduces cleavage of kininogen in the plasma, a critical step implicated in the pathogenesis of hereditary angioedema[1]. This mechanism underpins its role in preventing episodes of angioedema in patients.
Clinical Studies
- Phase 1 Trials: In initial clinical evaluations, Lanadelumab exhibited a favorable safety profile. Notably, the drug was associated with a marked reduction in the cleavage of kininogen in the plasma of hereditary angioedema patients[2].
- Ongoing Phase 3 Trials (as of 2017): Building on the positive findings from early-phase trials, two pivotal phase 3 studies are underway. These trials are specifically designed to assess the efficacy of Lanadelumab in preventing acute angioedema attacks in patients with hereditary angioedema[3].
Development and Designation
Lanadelumab was originally developed by Dyax Corp, a biopharmaceutical company with a notable track record in antibody research. Subsequent developmental phases have been taken over by Shire, further emphasizing the potential of this molecule.
Signifying its importance and promise, the U.S. FDA has conferred the "breakthrough therapy" designation upon Lanadelumab. Such a designation is reserved for drugs that demonstrate substantial improvements over existing therapies for severe or life-threatening conditions[4].
Conclusion
Lanadelumab offers a beacon of hope for patients afflicted with hereditary angioedema, a condition that can be debilitating and, in some instances, life-threatening. With its targeted mechanism of action and encouraging clinical results, the future looks promising for this novel therapeutic antibody.
References
- ↑ Zuraw, B.L. (2008). Hereditary angioedema with normal C1 inhibitor: Four types and counting. The Journal of Allergy and Clinical Immunology, 141(4), 884–885.
- ↑ Banerji, A., et al. (2017). Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine, 376(8), 717–728.
- ↑ Riedl, M.A., et al. (2018). Multicenter, randomized, double-blind, placebo-controlled study of lanadelumab for prevention of attacks in hereditary angioedema. JAMA Dermatology, 154(12), 1441–1449.
- ↑ U.S. Food and Drug Administration. (2019). Breakthrough Therapy. Retrieved from https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
